ダウンロード数: 121
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
j.reth.2015.06.002.pdf | 215.26 kB | Adobe PDF | 見る/開く |
タイトル: | A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem(-like) cells |
著者: | Hayakawa, Takao Aoi, Takashi Umezawa, Akihiro Ozawa, Keiya Sato, Yoji Sawa, Yoshiki Matsuyama, Akifumi Yamanaka, Shinya Yamato, Masayuki |
著者名の別形: | 早川, 堯夫 青井, 貴之 梅澤, 明弘 小澤, 敬也 佐藤, 陽治 澤, 芳樹 松山, 晃文 山中, 伸弥 大和, 雅之 |
キーワード: | Autologous hiPS(-like) cells Quality and safety of pharmaceuticals and medical devices Regenerative medicine Human stem cell-based products |
発行日: | Dec-2015 |
出版者: | Elsevier BV |
誌名: | Regenerative Therapy |
巻: | 2 |
開始ページ: | 81 |
終了ページ: | 94 |
抄録: | As a series of endeavors to establish suitable measures for the sound development of regenerative medicine using human stem cell-based products, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from autologous human iPS cells or iPS cell-like cells, taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-4, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human Induced Pluripotent Stem(-Like) Cells, ” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on September 7, 2012. The present paper addresses various aspects of products derived from autologous human iPS cells (or iPS cell-like cells), in addition to similar points to consider that are described previously for autologous human stem cell-based products. Major additional points include (1) possible existence of autologous human iPS cell-like cells that are different from iPS cells in terms of specific biological features; (2) the use of autologous human iPS(-like) cells as appropriate starting materials for regenerative medicine, where necessary and significant; (3) establishment of autologous human iPS(-like) cell lines and their characterization; (4) cell banking and/or possible establishment of intermediate cell lines derived from autologous human iPS(-like) cells at appropriate stage(s) of a manufacturing process, if necessary; and (5) concerns about the presence of undifferentiated cells in the final product; such cells may cause ectopic tissue formation and/or tumorigenesis. The ultimate goal of this guidance is to provide suitable medical opportunities as soon as possible to the patients with severe diseases that are difficult to treat with conventional modalities. |
著作権等: | © 2015 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
URI: | http://hdl.handle.net/2433/242858 |
DOI(出版社版): | 10.1016/j.reth.2015.06.002 |
PubMed ID: | 31245462 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。